Biotech Values

[DewDiligence]

ABBV/(JNJ)—…nobody expects anything to work in pancreatic anyway.

It’s nevertheless a negative signal for the applicability of BTK inhibitors such as Imbruvica in solid tumors.

One can see that this clinical failure is significant from an investment standpoint by turning the result on its head: i.e., if the trial in question had succeeded, it would surely have caused a material bump in ABBV’s (and even JNJ’s) valuation. So, the absence of such a bump is itself a notable event.